KL-A167 Injection Combined With Cisplatin and Gemcitabine vs Placebo Combined With Cisplatin and Gemcitabine in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma

NCT05294172 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

295

Enrollment

INDUSTRY

Sponsor class

Conditions

Nasopharyngeal Carcinoma
Recurrent or Metastatic

Interventions

DRUG: KL-A167
DRUG: Gemcitabine
DRUG: Cisplatin
DRUG: Placebo

Sponsor

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.